| Outcome Measures: |
Primary: Change in HbA1c, Change from baseline in Glycosylated Haemoglobin after 36 weeks of treatment., Week 0 to Week 36 | Secondary: Change in body weight, Change from baseline in body weight after 36 weeks of treatment., Week 0 to Week 36|Proportion of Subjects with HbA1c≤6.5%, Proportion of subjects with HbA1c≤6.5% after 36 weeks of treatment., Week 0 to Week 36|Proportion of Subjects with HbA1c<7%, Proportion of subjects with HbA1c\<7% after 36 weeks of treatment., Week 0 to Week 36|Change in FPG (fasting plasma glucose), Change from baseline in FPG after 36 weeks of treatment., Week 0 to Week 36|Change in FPG (fasting plasma glucose), Change from baseline in FPG after 52 weeks of treatment., Week 0 to Week 52|7-points SMPG profiles, Fluctuation of 7-point SMPG. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner,120 minutes after start of dinner, before bedtime., Week 0 to Week 36|Incidence and severity of adverse events, Severity (mild, moderate and severe) is assessed by investigator., Week 0 to Week 52+4 weeks follow-up
|
